Trial EUPAS34753
Publication Fernández Cruz A, AAC ASM, 2020
Dates: 3/4/2020 to 4/7/2020
| Methods | |
| Non-randomized study | |
| Location :
Single center / Spain Follow-up duration (days): 30 | |
| Inclusion criteria | Adult patients diagnosed with COVID-19 pneumonia according to WHO interimguidance, and complicated with ARDS and/or an hyperinflammatory syndrome,where included. |
| Exclusion criteria | NR |
| Type of analysis | Propensity score matching |
| Interventions | |
| Treatment
Methylprednisolone (*) Co-Intervention: Standard care |
|
| Control
Standard care Definition of Standard care: | |
| Participants | |
| N analyzed 463 participants (n1=396 / n2= 67) | |
| Characteristics of participants N=463 Mean age : 65.8 317 males Severity : Mild: n=0 / Moderate: n=165/ Severe: n=298 Critical: n=30 | |
| Primary outcome | |
| In the register % of patients presenting an event during the follow-up period.Event is defined as: progression to a score of 5, 6 or 7 on the 7-point Ordinale Scale (WHO)after admission by COVID-19. | |
| In the report in-hospital mortality | |
| Documents avalaible |
Protocol Yes. In Language other than English Statistical plan NR Data-sharing stated Yes |
| Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
Serious |
| Notes | * |